Sangamo Therapeutics, Inc.

Hello, everyone, and thank you for standing by. Welcome to the Sangamo second quarter of 2021 teleconference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press the star 1 on your telephone. Please be advised that today's conference is being recorded, and if you require any further assistance, please press the star 0. I would now like to hand the conference over to our speaker today, the head of the Corporate Communications, Ms. Erin Feingold. Please go ahead.

Good afternoon, and thank you for joining us today. With me this afternoon on this call are several members of the Sangamo Executive Leadership Team, including Sandy McCray, Chief Executive Officer. Mark McClung, Chief Business Officer. Pratusha Durebabu, Chief Financial Officer. Jason Fontenot, Chief Scientific Officer. Rob Schott, Head of Development. And Bettina Cockroft, Chief Medical Officer. Slides from our corporate presentation can be found on our website Sangamo.com under the Investors and Media section on the Events and Presentations page. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements relating to potential value drivers, clinical catalysts, and advancement of our preclinical pipeline, plans and timelines for enrolling and conducting clinical trials and presenting clinical data, potential clinical data outcomes, our 2021 financial guidance. our expectations regarding our financial performance and sufficiency of our cash resources, and other statements that are not historical facts. Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties that are discussed in our filings with the SEC, specifically our annual report on Form 10-K for the fiscal year ended December 31, 2020, as supplemented by our quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2021. The forward-looking statements stated today are made as of this date, and we undertake no duty to update such information except as required by law. On this call, we discuss our non-GAAP operating expenses. Reconciliation of this measure to our GAAP operating expenses can be found in today's press release, which is available on our website. Now, I'd like to turn the call over to our CEO, Sandy McRae.

Thank you, Erin, and good afternoon to everyone on the call. This is an exciting time at Sangamon, as we look forward to multiple clinical catalysts over the next several quarters, representing potential near-term value drivers. At the same time, we're advancing our promising preclinical pipeline that focuses on our differentiated CAR-T reg approach for autoimmune diseases and genome engineering for CNS diseases towards INDs, referencing potential mid-term value drivers. Beyond that, we continue to invest in early-stage research to further mine value from our core zinc finger platform. We continue to make steady progress on our wholly owned Fabry Disease Phase 1-2 clinical study. During the quarter, we dosed a fourth patient, and based on initial safety data for patients dosed to date, the Safety Monitoring Committee endorsed dose escalating to the third dose as planned under the study protocol. We're currently screening patients for the third dose cohort and expect to dose the first two patients in this third cohort by the end of the year. We will make a decision on when to first present initial data from this study, depending on clinical timelines, and we'll publicly announce our plans when available. In addition, we currently have three sites open in what we believe is the first in human CAR T-REX study, and we plan to enroll the first patient by the end of this year. We're very excited about this study. We believe this proof-of-concept study evaluating TX200 in kidney transplant rejection will help us understand CAR Treg pharmacology and biology in humans, as well as advance process development knowledge. We hope this study establishes a foundation for a portfolio of wholly owned CAR Treg therapies for autoimmune indications. In the fourth quarter of this year, we in Pfizer expect to present two-year results from the Phase 1-2 ALTA study in haemophilia A. We look forward to having a clearer understanding of durability through two years from the five patients in the high-dose cohort from the Phase 1-2 ALTA study, as well as from the Phase 3 data from additional patients that we expect to read out in 2022. Together, these data will be highly informative about the potential product profile. In addition, later this year, we and our partner Sanofi expect to share initial Phase 1-2 data from our Precision 1 study at an upcoming medical meeting. The study is investigating SAR 445136 for the treatment of sickle cell disease. We expect to report interim efficacy and safety data for the first four patients dosed with at least three months of follow-up. Finally, Biogen recently selected a fourth neurological disease gene target under a collaboration agreement, and we have begun early research activities on therapies addressing this target. This quarter, our former General Counsel, Gary Lowe, made the personal decision to leave Sango for another opportunity. We thank him and wish him well in his future. However, we are pleased today to announce that we have promoted Scott Willoughby to General Counsel and Corporate Secretary. Scott has contributed significantly to Sangamon, overseeing all corporate law and compliance matters since he joined us in March 2020. Scott has over 20 years of legal experience with expertise in corporate governments, SEC reporting, corporate finance, compliance, mergers and acquisitions, and transactions. In addition to Scott's appointment, our executive team was recently strengthened by the appointment of our new Chief Financial Officer, Patricia Darre-Bambo. Patricia has served as Sangamwus Principal Accounting Officer for nearly two years. She has contributed significantly with her wealth of experience and her proven track record in optimising financial strategy and operations, driving organisational change and building diverse teams. It is so pleasing to promote from within talented individuals and I look forward to Scott and Patricia's leadership. And with that, I'll turn the call over to Patricia for a financial update.